Education
About Us
Working with TipRanks
Follow Us
Mersana Therapeutics Inc (MRSN)
NASDAQ:MRSN
Upifitamab Rilsodotin
Non-Small Cell Adenocarcinoma, Platinum Resistant Ovarian Cancer
Phase I
Completed
First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b
Jul 18, 2024
―
Upifitamab Rilsodotin
Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic
Phase I
Completed
First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b
Jul 18, 2024
―
Xmt-2056
Her2-Positive Breast Cancer, Her2-Positive Gastric Cancer, Her2-Positive Non-Small Cell Lung Cancer, Her2-Positive Colorectal Cancer, Her2-Positive Tumors, Her2 Low Breast Cancer
Phase I
Recruiting
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Aug 08, 2022
―
Xmt-1660
Fallopian Tube Cancer, Endometrial Cancer, Ovarian Cancer, Breast Cancer, Triple Negative Breast Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma
Phase I
Recruiting
A Study of XMT-1660 in Participants With Solid Tumors
May 02, 2022
―
Upifitimab Rilsodotin
Fallopian Tube Cancer, Primary Peritoneal Cancer, High Grade Serous Ovarian Cancer
Phase III
Terminated
Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)
Mar 24, 2022
―
Carboplatin, Xmt-1536 (Upifitamab Rilsodotin)
Platinum-Sensitive Ovarian Cancer (Upgrade-A)
Phase I
Terminated
Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer
May 12, 2021
―
Xmt-1592
Ovarian Cancer, Nonsmall Cell Lung Cancer
Phase I
Terminated
First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b
May 15, 2020
―
Upifitamab Rilsodotin
Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic
Phase I/II
Active Not Recruiting
First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
Oct 17, 2017
―
Xmt-1522
Advanced Breast Cancer, Advanced Nonsmall Cell Lung Cancer, Advanced Gastric Cancer
Phase I
Completed
Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2
Oct 27, 2016
―
Xmt-1107
Neoplasm Metastasis
Phase I
Completed
A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors
Nov 10, 2009
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Mersana Therapeutics Inc (MRSN) have in its pipeline
MRSN is currently developing the following drugs: Upifitamab Rilsodotin, Upifitamab Rilsodotin, Xmt-2056. These drug candidates are in various stages of clinical development as the company works toward FDA approval.